162 related articles for article (PubMed ID: 23881566)
1. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial.
Cahn A; Mehta R; Preece A; Blowers J; Donald A
Clin Drug Investig; 2013 Sep; 33(9):653-64. PubMed ID: 23881566
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies.
Cahn A; Tal-Singer R; Pouliquen IJ; Mehta R; Preece A; Hardes K; Crater G; Deans A
Clin Drug Investig; 2013 Jul; 33(7):477-88. PubMed ID: 23784369
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
Kelleher DL; Mehta RS; Jean-Francois BM; Preece AF; Blowers J; Crater GD; Thomas P
PLoS One; 2012; 7(12):e50716. PubMed ID: 23284643
[TBL] [Abstract][Full Text] [Related]
5. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies.
Tal-Singer R; Cahn A; Mehta R; Preece A; Crater G; Kelleher D; Pouliquen IJ
Eur J Pharmacol; 2013 Feb; 701(1-3):40-8. PubMed ID: 23276660
[TBL] [Abstract][Full Text] [Related]
6. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Feldman G; Walker RR; Brooks J; Mehta R; Crater G
Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
[TBL] [Abstract][Full Text] [Related]
7. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
Mehta R; Hardes K; Brealey N; Tombs L; Preece A; Kelleher D
Int J Chron Obstruct Pulmon Dis; 2015; 10():15-23. PubMed ID: 25565796
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
Hu C; Jia J; Dong K; Luo L; Wu K; Mehta R; Peng J; Ren Y; Gross A; Yu H
PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
12. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Lipson DA; Barnhart F; Brealey N; Brooks J; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Martinez FJ; Singh D; Tabberer M; Wise RA; Pascoe SJ;
N Engl J Med; 2018 May; 378(18):1671-1680. PubMed ID: 29668352
[TBL] [Abstract][Full Text] [Related]
13. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
Mehta R; Hardes K; Kelleher D; Preece A; Tombs L; Brealey N
Clin Ther; 2014 Jul; 36(7):1016-1027.e2. PubMed ID: 24947493
[TBL] [Abstract][Full Text] [Related]
14. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.
Pleasants RA; Wang T; Gao J; Tang H; Donohue JF
Drugs; 2016 Mar; 76(3):343-61. PubMed ID: 26755180
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
Donohue JF; Anzueto A; Brooks J; Mehta R; Kalberg C; Crater G
Respir Med; 2012 Jul; 106(7):970-9. PubMed ID: 22498110
[TBL] [Abstract][Full Text] [Related]
17. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers.
Yang S; Lee L; Mallett S; Ayer J; Wolstenholme A; Pascoe S
Adv Ther; 2015 Feb; 32(2):157-71. PubMed ID: 25700806
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
19. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.
Manickam R; Asija A; Aronow WS
Expert Opin Drug Saf; 2014 Nov; 13(11):1555-61. PubMed ID: 25294427
[TBL] [Abstract][Full Text] [Related]
20. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study.
Mehta R; Kelleher D; Preece A; Hughes S; Crater G
Int J Chron Obstruct Pulmon Dis; 2013; 8():159-67. PubMed ID: 23569370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
